Home > Boards > US OTC > Medical - Drugs >

Creative Medical Technology Holdings, Inc. (CELZ)

CELZ RSS Feed
Add CELZ Price Alert      Hide Sticky   Hide Intro
Moderator: monte379, PIGEON RIVER PROSPECTIN,TN, docprep, WinInLife, ASKSCHLEG
Search This Board: 
Last Post: 5/18/2019 9:45:41 PM - Followers: 418 - Board type: Free - Posts Today: 0

















About Us
 

 

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is a commercial-stage biotechnology company focused on Urology and Neurology using stem cell treatments.  Through our own research and collaborations with leading academic institutions, CMTH has acquired a groundbreaking stem cell (Amniostem), developed proprietary protocols, built an extensive intellectual property portfolio, developed complete treatment offerings for erectile dysfunction, launched a 40-patient trial for ED at UCLA and are breaking new ground for treating stroke using our newly acquired amniotic fluid-based stem cell.  Our team consists of leading international researchers in regenerative medicine.  Our “science-first” approach to treatments ensures that all of our treatments are proven to be both safe and effective.  We are currently in the commercial stage of our bone marrow based stem cell treatment for Erectile Dysfunction known as CAVERSTEM, which is being marketed both nationally, and internationally.  




Contact Info


2017 W Peoria Avenue
Phoenix, AZ 85029
Phone: (833) 336-7636

  
ceo@creativemedicalhealth.com
coo@creativemedicalhealth.com

web: creativemedicaltechnology.com


https://www.otcmarkets.com/stock/CELZ/overview
http://www.creativemedicaltechnology.com


HELPFUL LINKS

 
Authorized Shares - 3,000,000,000

Outstanding Shares - 1,029,757,067
 






Company News


 
Creative Medical Technology Holdings, Inc. To Unveil Its Patented CaverStem™ Procedure For Erectile Dysfunction At International Urology Conference

PHOENIX, March 26, 2018
 

PHOENIX, March 26, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) will be exhibiting it's patented CaverStemTM stem cell procedure for erectile dysfunction at the annual American Urological Association (AUA) conference on May 18-21, 2018 in San Francisco.

According to the AUA "Last year's meeting welcomed more than 16,000 attendees from more than 100 countries around the world, underscoring the meeting's value to the global urologic community. This year's meeting will feature more innovative programming and educational offerings than ever before, giving physicians unparalleled access to groundbreaking research, the latest clinical guidelines and the most advanced technologies in urology." 

We invite all attendees to visit us at booth 5780

"Our cutting edge technology in autologous stem cell treatment for erectile dysfunction is anticipated to be received by the urologic community with great enthusiasm as our CaverStem TM procedure represents an all-natural alternative for those patients resistant to the use of PDE5 inhibitors such as Viagra and Cialis," said Thomas Ichim PhD, Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.

According to multiple publications, approximately 30% of the 30,000,000 men suffering from erectile dysfunction are resistant to such PDE5 inhibitors.

"Since beginning commercialization of our patented and tested CaverStemTM procedure in November 2017, we have received positive responses from the urology community in the limited cities marketed. We anticipate the introduction of our technology to the attendees of the largest annual urology conference, to promote nationwide interest in CaverStemTM,said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.

About the CaverStemTM procedure: CaverStem™ is a patented process involving extraction of a small amount of bone marrow from the patient, separating stem cells from the bone marrow using an FDA cleared device, followed by re-administration of the stem cells into the corpus cavernosa of the patient's penis. Two clinical studies have been conducted utilizing patient's own bone marrow stem cells administered into the penis, which demonstrated safety and signals of efficacy.

https://www.otcmarkets.com/stock/CELZ/news/Creative-Medical-Technology-Holdings-Inc-To-Unveil-Its-Patented-CaverStem-Procedure-For-Erectile-Dysfunction-At-Internat?id=187192

 




Creative Medical Technology Holdings Files Patent on Anti-aging Technology Using AmnioStem Stem Cells

PHOENIX, May 8, 2018
 

Creative Medical Technology Holdings announced today filing of patent application number 62663912 covering the use of its AmnioStemTM stem cells as a means of reducing/reversing natural aging. 

Previous studies by the Company have demonstrated that AmnioStemTM cells secrete factors that are capable of rejuvenating aged cells.  By encapsulating the cells outside of the body, so that the cells are in contact with the patient's circulation, the cells are permitted to secrete factors that may reduce aging, without having to inject the cells in the patient. 

The concept of using cells that are growing outside of the body as a means of modifying physiological activities has previously been performed and appears feasible.  Specifically, similar approaches to mixing patient blood with cells outside of the body have previously been attempted in the area of liver failure.  A clinical trial demonstrated feasibility of using cell culture of hepatocytes to act as a "liver assist device".  These devices are currently in Phase 3 of clinical trials1,2

The filed patent describes a similar approach to those used in liver failure, with the exception that instead of using hepatocytes outside of the body, the device uses AmnioStemTM amniotic fluid derived stem cells.

"Previous studies from Stanford University3 and Harvard University4 have shown that if the circulation of an aged mouse is connected to the circulation of a young mouse, various factors secreted by young mice induce an anti-aging/rejuvenating effects on organs/tissues of aged miceThrough this patent, we are aiming to recapitulate this effect, in an ethical and technically feasible manner." Said Dr. Thomas Ichim, the Company's Chief Scientific Officer. "What is stunning about the AmnioStemTM stem cell, which was licensed by the Company from the University of California San Diego, is that it possesses many regenerative features but is collected from non-controversial sources."

The AmnioStemTM stem cell is derived from amniotic fluid during the process of amniocentesisAmniotic fluid is typically considered medical waste.  Scientists at University of California San Diego have developed means of extracting and growing stem cells from the amniotic fluid.  These stem cells have been published to be capable of treating animal models of numerous diseases including stroke5, heart attack6, liver failure7, colitis8, diabetes9, emphysema10, and kidney injury11.  An important activity of amniotic fluid stem cells is that cells derived from one person can be used to treat other people, making them "universal donor" stem cells.

"The concept of using young blood to stimulate regeneration in aged individuals is attracting much attention in the area of regenerative medicine.  I am enthusiastic about the approach being developed by Creative Medical Technology Holdings, which overcomes some of the important roadblocks that prevent implementation of this novel and promising approach," said Amit Patel, MD, MS, Chief of Cardiothoracic Surgery University of Miami and coinventor of the patent.

"At Creative Medical Technology Holdings we are committed to advancing regenerative medicine to various areas of human suffering.  In contrast to other conditions, aging will occur in everyone," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "While the field of anti-aging medicine is filled with various false hopes and hype, we are attempting to address this problem cautiously and methodologically through testing our technology for safety and efficacy.'

"Our goal is to continue to internally develop and patent technology in the regenerative medicine space and to broaden our patent portfolio for future commercialization by the company and/or with other life science companies with complementary technology."


https://www.otcmarkets.com/stock/CELZ/news/Creative-Medical-Technology-Holdings-Files-Patent-on-Anti-aging-Technology-Using-AmnioStem-Stem-Cells?id=191516


 


 

"Urologist to the Stars" Dr. Alexander Gershman to attend American Urological Association conference to discuss the CaverStem™ Stem Cell Procedure for Drug Refractory Erectile Dysfunction

PHOENIX and LOS ANGELES, May 8, 2018
 

Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today that Dr. Alexander Gershman will attend the AUA conference on May 19th and 20th with Creative Medical Technology Holdings, Inc. to discuss the CaverStem(TM) procedure from the perspective of a physician treating patients.

Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center, began treating patients with the CaverStem(TM) procedure in December 2017, which involves extraction of a small amount of bone marrow, concentration of bone marrow derived stem cells, and subsequent administration to the patient.

"There is much excitement about stem cells revolutionizing many aspects of medicine. I am enthusiastic to be offering this cutting edge procedure to my patients, for which previous therapies have failed or are too invasive," said Dr. Gershman. "Numerous publications and a recent clinical trial at the Los Angeles Biomedical Institute at Harbor - UCLA Hospital in Torrance, CA, support the safety and feasibility of the CaverStem(TM) procedure. The biological basis of the bone marrow based treatment is that in patients with drug non-responsive erectile dysfunction, there is a deficit in function of smooth muscle and blood vessel cells. By administering the patient's own stem cells we aim to rebuild these damaged tissues, and thereby restore erectile function."

Creative Medical Health Technology Holdings is offering the CaverStem(TM) procedure to selected physicians in the USA, which qualify according to the Company's criteria. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.

"We are pleased to have one of the top opinion leaders of the urology community join us, as we present the CaverStem(TM) procedure to the attendees of the American Urological Association conference," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.

To all attendees please visit booth 5870 to meet the CaverStem(TM) team.


https://www.otcmarkets.com/stock/CELZ/news/Urologist-to-the-Stars-Dr-Alexander-Gershman-to-attend-American-Urological-Association-conference-to-discuss-the-CaverSt?id=191515
 

 

Creative Medical Technology Holdings Forms CaverStem International LLC

Subsidiary to concentrate on International Erectile Dysfunction Market

 

PHOENIX and LOS ANGELES, June 19, 2018

PHOENIX and LOS ANGELES, June 19, 2018 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of CaverStem International LLC, a majority owned subsidiary focused on commercializing stem cell therapy for erectile dysfunction to international physicians and their patients.

"Due to the enthusiastic response from international attendees at the American Urological Association conference held in May 2018, we've determined it is in the best interest of the company to form a subsidiary to pursue commercialization with physicians from around the world," said Timothy Warbington President and CEO of Creative Medical Technologies, Inc. and Managing Member of CaverStem International LLC.

Dr. Alexander Gershman, an internationally renowned urologist, lecturer, inventor and Scientific Advisory Board Member at Creative Medical Technology Holdings, Inc., will take on an expanded role with CaverStem International, utilizing not only his vast expertise but also his international relationships in the urology community to expand our physician base.  Dr. Gershman is one of the Managers and Members of this subsidiary. "We're excited that Dr. Gershman who was the first physician to treat patients commercially with the CaverStemTM procedure, is taking on this role with the company," Timothy Warbington said further.

"I am pleased to take on this expanded role as a Manager and Member of CaverStem International. As a treating physician I have experienced first hand the safety and efficacy of the CaverStemTM procedure and I'm excited to introduce our technology to my peers in the international urology community.  Since beginning to offer the CaverStem™ procedure in December 2017 I have treated multiple patients of which approximately 90% have reported positive improvements.  These are all patients for which pharmacological interventions such as Viagra and Cialis do not work," said Dr. Alexander Gershman.

Creative Medical Health Technology Holdings is offering the Caverstem™ technology to selected physicians in the USA, which qualify according to the Company's criteria.  Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com. For more information on the procedure go to www.caverstem.com.


 

Creative Medical Technology Holdings Aims to Treat Cancer Associated Wasting (Cachexia) Using AmnioStem Universal Donor Stem Cell

Company Sees Possible Access to AmnioStemTM for Cancer Patients under "Right to Try" Law

PR Newswire

PHOENIX, July 6, 2018

PHOENIX, July 6, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today initiation of a program aimed at treating cancer associated wasting, through the in-licensing of patent application #15/814284 entitled "Treatment of Cachexia Using Stem Cells and Products Thereof". 

Recently the Company announced data that the AmnioStem™ stem cell was superior to other stem cell types at reducing inflammatory mediators, including TNF-alpha1.  It is well known that inflammatory mediators generated by cancer have a pivotal contribution to cancer associated weight loss, formally termed "cachexia".  The Company believes that through suppression of inflammatory mediators, as well as direct anticancer effect of amniotic fluid stem cells2,3that AmnioStemTM may provide value in the treatment of advanced cancer patients.

Cachexia is a very severe complication of cancer: weight loss during treatment is associated with more side effects of chemotherapy, fewer cycles of chemotherapy, a lower response to therapy, and even decreased survival. It is estimated that more than 20% of cancer patients die due to cachexia, and more than 50% of patients die with cachexia4.

"One of the most horrific aspects of having cancer is associated cachexia, which to date is not a major focus of research for the Pharmaceutical and Biotechnology industry.  I strongly support the innovative approach that Creative Medical Technology Holdings is taking at dealing with this terrible condition," said Santosh Kesari, MD, PhD Chair and Professor of Department of Translational Neurosciences and Neurotherapeutics at Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John's Health Center in Santa Monica, CA.

"We are confident that once we have completed Phase I clinical trials to demonstrate human safety of this cell, we will be well positioned to allow access to end stage cancer patients under the Right to Try law," said Thomas Ichim, Ph.D, Chief Scientific Officer and Cofounder of Creative Medical Technology Holdings.

On May 30th, 2018 President Trump signed the Right to Try law, which allows access to experimental medicines to patients suffering from end stage conditions for which no effective treatment is available.  After signing the law, President Trump said the following, "With the Right to Try law I'm signing today, patients with life-threatening illnesses will finally have access to experimental treatments that could improve or even cure their conditions.  These are experimental treatments and products that have shown great promise, and we weren't able to use them before.  Now we can use them.  And oftentimes they're going to be very successful.  It's an incredible thing."

"I am very excited at the prospect of utilizing our patented AmnioStemTM technology to approach the terrible problem of cancer cachexia from a completely novel angle.  This approach, if successful, will buy cancer patients time, time which could bridge them to new therapies and thus give them a new lease on life," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com



 

Creative Medical Technology Holdings Announces Caverstem Contract For Russia

PR Newswire

PHOENIX, July 19, 2018

PHOENIX, July 19, 2018 /PRNewswire/ -- Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today that its subsidiary Caverstem International LLC has signed an exclusive contract with Promo Med Russia for the commercialization of its CaverStemTM technology.

As previously disclosed, Creative Medical Technology Holdings, Inc. formed the subsidiary CaverStem International LLC for the purpose of commercializing its erectile dysfunction technology to international physicians.  

Professor Dimitri Pushkar MD, Director of Urology at Moscow University, Urologist General of Russia and a decades long colleague of Dr. Alex Gershman was key in the fast paced movement of this agreement and moreover in establishing the practice of the CaverStemTM procedure in Russia.

"Upon meeting with Dr. Gershman and the CaverStemTM team at the American Urological Association conference in May, I became more familiar with the CaverStemTM technology and quickly identified it as a valuable treatment for the escalating erectile dysfunction problems in Russia. As physicians it is our responsibility to seek out and develop advanced technologies in medicine to improve the quality of our patients lives," said Dr. Pushkar.

"We are excited and appreciative that a physician of Dr. Pushkar's reputation is involved in expanding our technology to the international medical community. We also wish to thank Dr. Gershman, as his decades long relationships and stellar international reputation were instrumental in furthering our expansion of CaverStemTM," said Timothy Warbington, CEO of Creative Medical Technology Holdings.

Because of our mutual desire for a more immediate implementation of CaverStemTM , CELZ VP of Sales, Gary Mells is currently in Russia meeting with multiple urologists and officials. We are beginning the applications and other regulatory paperwork required by the United States and Russia to import our technology," Mr. Warbington further said.   

According to The Pravda Report, up to 90% of males in Russia suffer from some degree of erectile dysfunction.

"The promise of our cutting edge stem cell technology transcends international borders and presents a great opportunity to the company, treating physicians and their patients," said Gary Mells.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a clinical stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.  For more information on our CaverstemTM procedure please go to www.caverstem.com

 


 

Shareholder Update: Creative Medical Technology Holdings, Inc.

PR Newswire

PHOENIX, Aug. 14, 2018

PHOENIX, Aug. 14, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities.

Debt: Since our last 8k on debt reduction an additional $268,858.00 has been extinguished.

CaverStemTM: Domestic recruitment, vetting and training of physicians on the CaverStemTM program for the use of the patients own stem cells for the treatment of erectile dysfunction is continuing post AUA Conference in May 2018.

We wish to welcome some of the physicians in the CaverStem program;

Elias Said, MD and Mark Bieri, MD located in Las Cruces, NM. (caverstem-nm.com)

Victor Liu, MD located in San Francisco, CA, (caverstem-sanfrancisco.com)

David Brown, MD located in San Diego, CA,  (caverstem-sandiego.com)

Barton Wachs, MD located in Orange County, CA, (caverstem-oc.com)

Sheldon Freedman, MD located in Las Vegas, CA,  (caverstem-lasvegas.com)

Perinchery Narayan, MD at North Florida Urology with offices in Orlando, Ocala, Gainsville, St. Augustine and Palatka, FL. (caverstem-northflorida.com)

CaverStemTM International:

Implementation of our contract with Promo Med continues to move forward. We are also currently working with Dr. Alexander Buchmann with Alto Uro in Bern Switzerland to establish the CaverStemTM program in Switzerland, Germany and Austria. We are pleased with the opportunity to work with a highly regarded physician such as Dr. Buchmann to expand CaverStemTM in Europe.

CaverStemTM Clincal Trial: As per our contract with LA BioMed, the results will be made available 12 months after the last patient was enrolled. This will occur the end of August 2018. Once the data is received, analyzed and peer reviewed, the results will be jointly released by our company and LA BioMed.

American Urological Association Regional Conference: We will be exhibiting at this conference in ChicagoSeptember 5-9, 2018.

StemSpineTM: This patented technology for the use of stem cells for the treatment of degenerative disc disease represents the entry into a multi-billion dollar market. The StemSpineTM model is the use of stem cells from bone marrow from the as with the CaverStemTM program.

AmnioStemTM: The AmnioStemTM program is meeting our expected development milestones.

Stroke, Medical Wasting, Radiation Toxicity and other patents: Our intellectual property portfolio is meeting our expected milestones and we intend to release information as our progress continues.

Summary: We have faced challenges but we continue to grow our programs strategically and efficiently. We are optimistic with the progress and fundamentals of our company.

We wish to thank our shareholders for their continued support.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.  For more information on our CaverstemTM procedure please go to www.caverstem.com



 

Shareholder Update: Creative Medical Technology Holdings, Inc.

PR Newswire

PHOENIX, Sept. 4, 2018

PHOENIX, Sept. 4, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities.

CaverStemTM: Domestic recruitment, vetting and training of physicians on the CaverStemTM program for the use of the patients own stem cells for the treatment of erectile dysfunction is continuing.

We wish to welcome Dr. Peter Niemczyk with The Center for Sexual and Urinary Function in Phoenix, AZ. Dr. Niemczyk holds Board Certifications in Urology and in male and female sexual dysfunction.

We are pleased to announce the addition of Amy Goldberg to the Creative Medical Technology Holdings sales team. Ms. Goldberg has decades long experience in medical device sales and will be concentrating on expanding the CaverStemTM program to physicians in the Eastern United States.

CaverStemTM International:

Russia: Implementation of our contract with Promo Med continues to move forward.

Switzerland: We AGAIN wish to welcome Dr. Alexander Bachmann and Alta-Uro in Bern, Switzerland. We are excited that CaverStemTM will be performed by such highly regarded physicians.

Germany and Austria: We are continuing discussions to expand CaverStemTM in these countries with the assistance of Dr. Bachmann and lead by Dr. Alexander Gershman, a Managing Member of CaverStem International LLC.

Italy: We have been approached by a very reputable physician interested in our CaverStemTM program. We are optimistic that in a near future press release we will have the opportunity to welcome Dr. Antonini from Antonini Urology in Rome, Italy to CaverStemTM. This is very encouraging as news of our expansion in Europe has resulted in physicians reaching out to the company to become involved.

CaverStemTM Clinical Trial: To add to our press release on August 14, 2018, once the trial has reached 1 year from the last patient enrolled, which was August 28th, the trial data collected by LA Bio Med will be submitted for peer review. Once this review is completed, our company and LA Bio Med will jointly publish the results. We understand the eagerness for trial results however as is our policy in all matters, we must follow the customary and contractual process. We will advise anticipated dates in near future releases. 

American Urological Association Regional Conference: We will be exhibiting at Booth 313 in Chicago on September 6and 7, 2018. We encourage all physicians attending to stop by and meet the CaverStemTM team.

Female Sexual Dysfunction: With the addition of physicians that practice in the area of both male and female sexual dysfunction we have determined that it is an appropriate time to begin development of our program related to the treatment of female sexual dysfunction. Based on publications, including The Cleveland Clinic, up to 43% of women suffer from some degree of sexual dysfunction which in many cases may be caused by the lack of blood flow. This technology which is similar to the CaverStemTM technology for the unexpanded and minimally manipulated use of the patients own bone marrow derived stem cells is designed to aid in the increase of sensitivity by increasing blood flow. We are currently developing a brand identity for release to specific physicians experienced in the treatment of female sexual dysfunction.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.  For more information on our CaverstemTM procedure please go to www.caverstem.com

 

Shareholder Update: Creative Medical Technology Holdings, Inc.

PR Newswire

PHOENIX, Sept. 24, 2018

PHOENIX, Sept. 24, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its progress:

Debt: We have entered into an agreement with three institutional investors in order to wrap up existing debt and provide working capital. These parties intend to provide support to the company through its commercialization of the CaverStemTM program and for future programs being developed. An 8k is being prepared and will be filed in the coming days specifying the terms. The agreement comes with better terms than were previously available and is expected to provide the necessary funding until which time as the company is generating sufficient cash flow to support operating activities.

CaverStem International: After completing meetings between the company and the medical team in Russia last week, it has been determined that the first patients will be scheduled for the CaverStemTM procedure this October.

We also are progressing with the CaverStemTM program in Switzerland and expect to release more information on the treatment of patients in this region soon.

We are pleased with the progress of CaverStem International in the few months since inception and wish to thank the international physicians for their invaluable assistance in its development.

CaverStemTM domestic activities: We are continuing to present the CaverStemTM program to physicians across the United States. Multiple leads were generated from our last AUA conference in Chicago in early September. Physicians that have contractually agreed to become involved with our program are in various stages of training and scheduling of patients. We continue to build brand awareness of CaverStemTM in the cities where the current physicians are located and this will be expanded as other physicians become involved. Our website CaverStem.com will be continually updated, adding new physicians.

Female Sexual Dysfunction: We are continuing the development of our patent pending technology. We are excited that this program, with the working name of FemCelz, will be ready to unveil at medical conferences in the very near future.

Additional conferences in 2018: We intend to present at the Sexual Medicine Society of North America conference in Miami on November 8-11, 2018. Dr. Gershman, Dr. Liu and members of the CaverStemTM  team will be in attendance. We will issue a specific press release in the coming days of our attendance and booth number. We are excited with the prospect of meeting new physicians from around the world who specifically treat male and female sexual function.

In response to emails from shareholders seeking specific information on operating activities, it is our policy to release information via press releases and SEC filings. We understand the desire for real time information, however information must be properly disclosed to the public. Advanced information provided to individuals could present an unfair advantage and thus cannot be disclosed. We appreciate our shareholders understanding of our policy to comply with all regulations on this matter.

We wish to extend our appreciation for the support of our shareholders, many of which have been vested in the company for several years, and to new shareholders who have recently become acquainted with us. The Officers and Directors will continue to devote our time and efforts to build the fundamentals of the company and to execute on our multitier business plan.   


 

Shareholder Update: Creative Medical Technology Holdings, Inc.

PR Newswire

PHOENIX, Oct. 17, 2018

PHOENIX, Oct. 17, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:

Creative Medical Health, Inc. shall convert $100,000.00 of deferred management compensation to CELZ stock at a VWAP of $0.0225 per share, which will result in 4,444,444 shares of CELZ stock being issued to Creative Medical Health, Inc. The shares shall be restricted for a minimum of six months. As evidenced in the past, Creative Medical Health has not sold any shares of CELZ stock and it is not the intent to sell CELZ shares in the foreseeable future.

CaverStem International: As we advised in our September 24, 2018 Shareholder Update, it was our intent to treat the first patients in Russia in October. The CaverStem team is in Russia meeting with the physicians and their staff in preparation for the procedures to begin on October 19th.

A press release will be issued in the days following October 19th to provide further details, including the observations of the physicians involved.

We also are progressing with the CaverStem™ program in Switzerland and expect to release more information on the treatment of patients in this region soon.  Interest in the CaverStem™ program also remains strong in other EU countries. Setting up such relationships and navigating all legal obligations to conduct business in each country takes a great deal of effort and time on the part of CaverStem™ executives and our counterparts in each medical practice. As we reach milestones as we have in Russia, future disclosure will be made.

We are pleased with the progress of CaverStem International in the few months since inception and wish to thank the international physicians for their invaluable assistance in its development.

CaverStem™ domestic activities: We are continuing to present the CaverStem™ program to multiple interested physicians across the United States. Physicians that have contractually agreed to become involved with our program are in various stages of training and scheduling of patients.

We are continuing to build brand awareness of CaverStem™ to patients in the cities where the current physicians are located and this will be expanded as other physicians become involved. In order for interested parties to keep updated on our domestic progress we suggest they refer to our website at CaverStem.com for the growing list of affiliated physicians.

LA Biomedical Institute clinical trial: As we've previously advised, once the data is fully compiled, it is our intent to disclose the data via a joint publication with LA Bio Med as contractually agreed upon as well as submission to clinicaltrials.gov. The CaverStem™ team members involved in this aspect of the business are working with LA Bio Med to bring this to fruition.

Again, in response to direct inquiries from shareholders seeking specific information on operating activities, it is our policy to release information via press releases and SEC filings. We understand the desire for real time information, however information must be properly disclosed to the public. Advanced information provided to individuals could present an unfair advantage and thus cannot be disclosed. We appreciate our shareholders understanding of our policy to comply with all regulations on this matter.

We wish to extend our appreciation for the support of our shareholders, many of which have been vested in the company for many years and to new shareholders who have recently become acquainted with us. We are confident in our company and we are continuing to devote our time and efforts to build on our fundamentals and to execute on our multitier business plan.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.  For more information on our Caverstem™ procedure please go to www.caverstem.com


 

Creative Medical Technology Holdings, Inc. Announces New Design To Caverstem Website Including New Features For Physician/Patient Engagement

PR Newswire

PHOENIX, Nov. 6, 2018

PHOENIX, Nov. 6, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today that as a continuation of the Brand Building of its CaverStemTM technology, it has awarded a contract to PatientGain Medical Marketing for the new design of its CaverStemTM website and to provide online strategy with a focus on acquiring and engagement of new patients for physicians offering the CaverStem™ procedure.

"Upon evaluating different medical marketing platforms and reviewing PatientGain's technology and deep healthcare industry knowledge, we determined that their system that covers healthcare CRM, medical website creation for conversion, Search Engine Marketing, HIPAA Compliant Facebook Apps, Texting/SMS marketing, Email Marketing, content creation and enterprise level support fit our needs," said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.

"We are appreciative and honored that a company like Creative Medical Technology Holdings is using PatientGain's Medical Marketing platform for CaverStem™ marketing across online channels including Web, Social Media, Email and Texting/SMS with HIPAA compliance. Our technology for healthcare marketing is being used by medical professionals in the USA and Canada and we are excited to be part of the CaverStemTM expansion," said Sal Khan, CEO of PatientGain. 

PatientGain's data shows that out of a sample of 3450 Medical Clinics in USA, only 4.3 percent clinics have a results driven online patient acquisition and engagement marketing plan. 

"In addition to gaining much greater online exposure for the CaverStemTM brand, by utilizing this technology CaverStemTM will interface with each physician's office to facilitate real time responses to patient inquiries and questions. As the CaverStemTM network grows we will be able to scale and maintain our efficiency in communicating with physician's and patient's, scheduling physician consultations and follow up appointments, all conducted under HIPAA compliance," Mr. Warbington further said.

Physician's in several cities are currently being trained on the use of the PatientGain platform and the newly designed Caverstem.com website is expected to launch within the next 10 days.

Please visit CaverStem.com to view our website and follow us on Facebook, Twitter, Instagram and You Tube.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a clinical stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com. For more information on our CaverStemTM procedure please go to www.caverstem.com.



 

Shareholder Update: Creative Medical Technology Holdings, Inc.

PR Newswire

PHOENIX, Nov. 14, 2018

PHOENIX, Nov. 14, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:

The company has timely filed its 10Q on 11-14-18, contained in the 10Q is predominantly financial information so as is customary we are providing an update to our Shareholders;

To summarize what is being discussed herein;

  1. We are continuing to recruit physicians in the USA and abroad.
    Patients are being treated in the USA and abroad.
    We are continuing to expand our marketing capabilities.
    We are continuing to develop our patent portfolio.
    We are cash flowing.
    We are continuing to grow the business.

CaverStem™ domestic activities: As previously reported, we are continuing marketing to physicians across the United States. There are currently 14 locations at various stages of development, training marketing, recruiting and treating patients. We are recruiting additional marketing representatives to gain increase our exposure to physicians.

CaverStem.com; since implementing Patient Gain on 11-5-18, we have trained physicians and their staff in five locations. The primary training involves use of the CRM for patient recruitment, interaction between the physician and the patient and patient retention. All in HIPAA compliance. The responses to the benefits of this platform and its ease of use has been positive. Training of other physicians is ongoing.

Implementing the Patient Gain platform at this time is of great value as increased proficiency in data management is expected to result in reaching a much larger potential patient market with an ongoing reduction in patient acquisition costs and appointment scheduling and patient follow up directly with each physician's office, which also is expected to increase efficiency and reduce administrative costs. The platform enables the company to quickly replicate and implement our system with each physician joining CaverStem™, resulting in much greater efficiency as we scale the business upward.

CaverStem International: As was announced by publication across social media outlets and our press conference, the company successfully sponsored the treatment of two patients in Moscow by Dr. Dmitri Pushkar, Urology General of Russia using the CaverStem™ procedure.

We also are progressing with the CaverStem™ program in Switzerland and expect to release more information on the treatment of patients in this region soon. Interest in the CaverStem™ procedure remains strong in other EU countries. Setting up such relationships and navigating all legal obligations to conduct business in each country takes a great deal of effort and time on the part of CaverStem™ executives and our counterparts in each medical practice. As we reach milestones as we have in Russia, future disclosure will be made.

LA Biomedical Institute clinical trial: As we've previously announced, it is our intent to disclose the data via a joint publication with LA Bio Med as contractually agreed upon as well as submission to clinicaltrials.gov. The CaverStem™ team members involved in this aspect of the business are working with LA Bio Med to bring this to fruition.

FemCelz; as previously announced, we are progressing with the development of the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Following the same model as CaverStem™we anticipate launching this program in Q1 2019.

Revenue; our revenue has increased in Q3, it was however impacted by delays in training and launch of physicians. The company determined that delays in training some physicians until which time as the Patient Gain technology was implemented and our Generation 2 device technology was secured was of benefit to the company, the physicians and to their patients than booking sales in a given quarter opposed to the following quarter.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.  For more information on our Caverstem™ procedure please go to www.caverstem.com

 

Creative Medical Technology Holdings, Inc. December 2018 Shareholder Update

PR Newswire

PHOENIX, Dec. 27, 2018

PHOENIX, Dec. 27, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:

As we end 2018 we look forward to continuing to reach multiple milestones in 2019.

CaverStemTM domestic activities: As previously reported, we are continuing marketing to physicians across the United States. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month.

We anticipate reaching financial self-sufficiency by revenues from sales in 2019.

Physician Marketing Campaigns: Scheduled for release in January 2019, CaverStemTM will begin a series of mailer and email campaigns introducing the CaverStemTM procedure to licensed physicians in the areas of urology, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's our goal to reach out to a minimum of 2500 new physicians each month by these methods.

Brand Awareness to Patients: Scheduled for launch in January 2019, CaverStemTM will increase its online presence on Social Media by sponsorships and banner advertising on websites and search engines attracting the active male. We are currently negotiating an advertising campaign in Los Angeles as our first city to expand into print and radio advertising.

CaverStemTM International: As was announced by publication across social media outlets and our press conference, the company successfully sponsored the treatment of two patients in Moscow using the CaverStemTM procedure. Treatment of patients is ongoing with positive results and is anticipated to steadily increase in 2019. Physicians in Switzerland and Italy are being scheduled for training and patients are being recruited.

CaverStemTM clinical trial: We understand the eagerness to receive published data. We are continuing to work towards this goal of publication of the results as soon as possible.

FemCelzTM; as previously announced, we are progressing with the development of the FemCelzTM procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. We are preparing the patient protocol and designing the website in anticipation of this launch in Q1. Many of our existing CaverStemTMaffiliated physician's also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelzTM program.

U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients in the past 90 days with excellent results. By replacing the centrifuge technology with our Generation 2 technology we realize the following benefits;

  1. Reduced bone marrow harvest from 60cc to 20cc.
    Higher cell count (less blood harvested).
    Reduced procedure time.
    Reduced startup cost for physician by eliminating centrifuge.

StemSpineTM: In order to concentrate our efforts on CaverStemTM domestic and international and FemCelzTM, StemSpineTM is expected to launch in late 2019. We feel it is in the best interest of the company to dedicate much of our resources to continue to build those brands and our cash flow before commercializing StemSpine.

AmnioStemTM: We are continuing to accumulate data in order to file for an FDA IND on the use of our amniotic stem cell for the treatment of stroke. We will advise milestones in subsequent filings.

Other patent pending technologies: We continue to prosecute our patent applications with the USPTO.

Acquisitions in 2019: We anticipate acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. in Q1 2019. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStemTM and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStemTM and FemCelzTM brands.  The benefit to the company will be

  1. Additional revenue sources from licensing, marketing and administrative fees as allowed for a Medical Service Organization (MSO).
    Additional revenue from sale of our medical equipment.
    Greater combined brand awareness by cross marketing.

We wish everyone a Happy New Year and the CELZ team will continue to do our best to build the fundamentals of the company, which we believe are stronger than ever.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.  For more information on our CaverStemTM procedure please go to www.caverstem.com

 

PHOENIX, Feb. 12, 2019

PHOENIX, Feb. 12, 2019 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of it's activities:

This update addresses the goals set for Q1 2019 with regard to the ongoing commercialization of the CaverStem™ and FemCelz™ components of our company.

We are reaching those goals.

We are continuing to cash flow from sales and deposits and we expect revenues to increase each quarter.

CaverStem™ domestic activities: In 2019, using our Generation 2 bone marrow aspiration system, we have already trained 2 physicians and are training 3 additional physicians in March and April.  As additional physicians become involved we will schedule training and marketing campaigns.

To elaborate on our process, once a doctor has been vetted and approved, the company begins a marketing campaign in the physicians city and surrounding areas for patients interested in the procedure. Once 5 patients are scheduled on a specific day that coincides with the physicians schedule and that of our CaverStem™ trainer and Marketing Director the training date is scheduled.

For the benefit of the physician and in building the CaverStem™ brand our Marketing Director shoots video interviews and takes photographs on location.  He also discusses with the physicians their marketing strategy and goals. This gives the company an insight into the physicians practice and marketing needs in his community and marketing/comarketing opportunities.

The company produces the videos and photographs, patient brochures, in office banners, inclusion on CaverStem.com, all social media platforms and company marketing campaigns on behalf of the physician. The company begins the brand building of CaverStem™ via Google Adwords. Banner advertising and social media in the physicians city and surrounding areas. Banner ads have been designed  to increase our web presence as previously disclosed.

We are currently scripting a 30 second and 60 second television commercial that will be edited with each physicians information. The advertisements are intended to air regionally on networks such as MSNBC, CNN, Fox News, ESPN, The Golf Channel and The History Channel. These networks have the ideal demographics for potential CaverStem™ patients.

Physician Marketing Campaigns: We have begun the physician marketing campaign and have sent out the first mailers in Januray We have received numerous email inquiries and we are reaching out and scheduling interviews. This process involves an in depth series of emails and calls with questions and answers from the physician and the Company. Once both sides agree a contract is signed.

We intend to duplicate this mailer to an additional 2500 physicians every 30 days or as appropriate.

CaverStem™ International: Our progress in Russia continues. As was announced on our social media sites Dr. Gabrielle Antonini will treat the first 5 patients in Rome on February 16th. We wish to again welcome Dr. Antonini and we look forward to a successful relationship.

CaverStem™ clinical trial: We understand the eagerness to receive published data. We are currently working on our paper for publication as soon as possible.

FemCelz™; we've made great progress in the last 30 days. The procedure protocol has been completed and submitted to 4 of the existing CaverStem™ physicians that also practice female sexual function medicine. We are developing content for the FemCelz.com website and FaceBook page to launch very soon. FemCelz is commercializing.

A paper on the FDA approved Generation 2 bone marrow harvest technology was published in The Journal of Translational Medicine in January 2019 coauthored by Dr. Amit Patel and Dr. Thomas Ichim. We encourage our shareholders to read this publication so that you may better understand the benefit of this technology.

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1750-x 

The acquisition of the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. will be completed by the end of this quarter. The company will then begin to offer this to new and existing physicians.

The company will from time to time post announcements via social media. This includes FaceBook pages CaverStem, CaverStem International, Urology Updates, Fem Celz and Creative Medical Technologies. Other social media sites will include You Tube, Instagram and Twitter. 

We continue to work on all aspects of the company and updates will be provided as milestones are met.

 

Creative Medical Technology Holdings, Inc. March 28, 2019 Shareholder Update

PR Newswire

PHOENIX, March 28, 2019

PHOENIX, March 28, 2019 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:

CaverStem™ domestic activities: As previously reported, we are continuing marketing to physicians across the United States. Since our last shareholder update several physicians have joined CaverStem™ and are in the process of training and patient acquisition.

We have added physicians in Hawaii, California, Ohio, Texas and Tennessee. We will continually add the new physicians to the CaverStem™ website, begin the patient awareness campaign in each area and schedule physician training.

These physicians came to us through our physician marketing program as previously disclosed. We are continuing to use this marketing tool with mailers and emails with follow up personal or telephone communication with physicians across the country.

We are always working to get physicians trained as soon as possible. In order to properly train each physician, we require a minimum of 5 patients. This requires scheduling all patients, the physician and our trainer. This process has caused delays, therefore we have added additional medical personnel to travel to each physicians office to train. With this increased flexibility on our part we anticipate a reduction in such delays.

As previously disclosed, our patient marketing campaign has relied heavily on social media with the use of Google Ad Words and banner advertising. We believe social media is a great resource as 80% of patients find us, using their phones and tablets. In order to continue to grow patient awareness print advertising is now being used and we are continuing to develop our television commercial which will be edited to direct patients to each physician in their area.

CaverStem™ International: We have successfully treated our first six patients in Italy and other patients are scheduled. Due to the increased international demand and to compliment our existing relationship with Scott Shea, CEO of Aspire Medical in Munich, Germany with whom we enjoy a phenomenal relationship, Thomas Bianchi has joined the company as our international sales representative. Mr. Bianchi has decades long experience in medical device sales, having worked for companies such as Stryker and Medtronics.  With Scott and Thomas on the CaverStem™ team we expect to continue to grow our international physician base not only in recruiting new physicians but in more effectively servicing existing physicians.

Progress in Russia has been much slower than expected. Government exemptions are required for the ongoing import of our device. This is a slow and tedious process in getting approval, therefore our progress has been delayed. We will continue with this process and maintain great faith in our relationship with Promo Med and our expansion in to this sizable market.

CaverStem™ clinical trial: As we've previously advised, we are working on our paper for publication. This is ongoing and in compliance with our contractual obligations. Once our paper has been approved by The Journal of Translational Medicine and a publication date advised we will advise.

Additionally, we have designed an electronic patient registry that is intended to include data from our clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and our second generation, needle only,  mini bone marrow aspiration technology drawing a maximum of 20cc of bone marrow. Recent publications have disclosed that with the second generation needle technology a larger amount of pure cell product is harvested because of a reduction in dilution of blood, thus requiring a reduced bone marrow aspiration. The registry will enable the company to gather and maintain ongoing HIPAA compliant information on patient demographics, history and treatment progress. Patient names and addresses will not be included on the registry or disclosed to the company.

We have received positive feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction.

FemCelz™: As previously announced, we are progressing with the development of the FemCelz™ procedure for the treatment of female sexual dysfunction.

Our progress in Q1 has included;

  1. Development of the protocol.
    Distribution of protocol to numerous physicians.
    Scheduling of the first patients for treatment.
    Ongoing design of the FemCelz website, to be launched in early April.
    Design of social media campaign towards female patients.
    Marketing to physicians in this space.

Expanding exposure of the company: We recently released a corporate video for the purpose of expanding recognition of the company to multiple groups including the financial and medical sectors. We will continue to utilize all legal means of increasing awareness of CELZ and its technologies. To increase shareholder value.

We are currently finalizing the 10k with our CPA, attorneys and PCAOB accountants.



 

PHOENIX, April 30, 2019

PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:

As we are releasing updates on a regular basis, we will only cover new activities. The absence of reporting on a specific area of our business should not be construed as a lack of concentration in that area but due to the short window of time between shareholder updates. We appreciate our shareholders' desire for "real time" information but some aspects of our business take time.

CaverStem™ domestic activities: We are continuing marketing to physicians across the United States. Since our last shareholder update an additional five physicians have expressed interest in joining CaverStem™. We are currently vetting those physicians and will submit contracts for their review and signature. Once contracts are in place, we will schedule training and begin marketing for patient awareness.

These physicians came to us through our physician marketing program. We are continuing to use this marketing tool with mailers and emails with follow up telephone communication with physicians across the country.

As previously disclosed, we have and will continue to use social media to build patient awareness with the use of Google Ad Words and banner advertising. We believe social media is a great resource as 80% of patients find us, using their phones and tablets. In order to continue to grow patient awareness print advertising is now being used and we are continuing to develop our television commercial which will be edited to direct patients to each physician in their area.

Dr. Narayan and his staff at North Florida Urology were trained on April 24th with five patients successfully treated. Training for Dr. Liu in San Francisco is scheduled on May 2nd and Dr. Sanderson in Honolulu will be trained in May. Other physicians are scheduled the first of June.

Patient testimonials discussing the procedure and the positive results are being filmed and will be posted on our caverstem.com website and our social media pages.

CaverStem™ International activities: We are continuing to treat patients in Italy and the first patients treated within the past 2 months have expressed positive results. This will be covered in a separate press release by Dr. Antonini and the company.

Additionally, our electronic patient registry is complete and is being forwarded to physicians. This registry is intended to include data from our clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and our second generation, needle only, mini bone marrow aspiration technology drawing a maximum of 20cc of bone marrow. Recent publications have disclosed that with the second generation needle technology a larger amount of pure cell product is harvested because of a reduction in dilution of blood, thus requiring a reduced bone marrow aspiration. The registry will enable the company to gather and maintain ongoing HIPAA compliant information on patient demographics, history and treatment progress. Patient names and addresses will not be included on the registry or disclosed to the company.

We have received positive feedback from treating physicians in the United States and Europe of a 70% to 100% efficacy in their patients. This percentage may fluctuate depending on the age and health of the patients and cause and severity of their erectile dysfunction.

FemCelz™: as previously announced, we are progressing with the development of the FemCelz™ procedure for the treatment of female sexual dysfunction. The first patients are scheduled for May 2nd in San Francisco. Additional patients are being scheduled in other cities.

We continue to move forward on all aspects of our business. The dedication of our team towards building the fundamentals of the company and shareholder value remain as strong as ever and the addition of medical industry veterans allows us to grow the company on a domestic and international level at a faster pace than at any time since inception of the company.

We would also like to thank our shareholders for their support, including the many shareholders from the medical field who have expressed positive feedback on our progress.

We are currently finalizing our Q1 financials and expect to file by the May 15, 2019 deadline.

Stem Cell Technologies



 


 
DAILY CHART WEEKLY CHART
   
CELZ
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CELZ News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/15/2019 05:27:11 PM
CELZ News: Current Report Filing (8-k) 05/08/2019 06:44:37 AM
CELZ News: Current Report Filing (8-k) 04/02/2019 04:08:03 PM
CELZ News: Annual Report (10-k) 04/01/2019 04:42:05 PM
CELZ News: Current Report Filing (8-k) 03/05/2019 05:20:27 PM
PostSubject
#82212  Sticky Note News from Italy is a home run and NSX 05/06/19 01:25:01 PM
#82152  Sticky Note CELZ News 5/6/2019..CaverStem Stem Cell Treatment Of Erectile PIGEON RIVER PROSPECTIN,TN 05/06/19 08:57:21 AM
#80942  Sticky Note This is all that matters.......but don't trust me docprep 04/15/19 04:52:31 PM
#76891  Sticky Note I bought back into CELZ yesterday. Surly Oracle 02/28/19 09:03:58 AM
#72995  Sticky Note Updated CELZ DD After AUA18 JBizzle703 01/17/19 06:21:19 PM
#34971  Sticky Note Everyone, this board is for the discussion of IH Admin [Macy] 06/23/18 07:56:50 PM
#83913   Box is bigger than “if” by one letter, cover2 05/18/19 09:45:41 PM
#83912   IF is a BIG word: where is THE uvaphd 05/18/19 08:51:44 PM
#83911   I imagined that all that was well known uvaphd 05/18/19 08:50:07 PM
#83910   You mean aquarium, not barrel. cover2 05/18/19 08:44:04 PM
#83909   I’m out. It’s like shooting fish in a gint1 05/18/19 07:58:13 PM
#83908   I guess you missed this: FemCelz is a gint1 05/18/19 07:55:50 PM
#83907   Sorority procedure? Which college, ? cover2 05/18/19 07:46:13 PM
#83906   FemCelz is a proprietary procedure using your own gint1 05/18/19 07:41:59 PM
#83905   Where r the boxes? cover2 05/18/19 07:40:16 PM
#83904   FemCelz is a proprietary procedure using your own gint1 05/18/19 07:33:32 PM
#83901   Shhhhhhhhh, that whooshing is your money traveling the cover2 05/18/19 07:21:44 PM
#83898   Ship without a captain. Mute silence so cover2 05/18/19 07:12:14 PM
#83897   For the new eyes: CaverStem.com gint1 05/18/19 07:02:34 PM
#83893   And broken windows I bet gint1 05/18/19 05:35:48 PM
#83892   Warbington owned a strip club right. P and Alexxdj1 05/18/19 05:34:19 PM
#83891   You forgot to mention this: CELZ....Stem Cell Treatment gint1 05/18/19 05:32:39 PM
#83890   CELZ....Stem Cell Treatment For Erectile Dysfunction (ED) CaverStem™ Uses gint1 05/18/19 05:29:04 PM
#83889   Nice to dream Chaka, but let’s get over Lonewolf1 05/18/19 05:28:20 PM
#83888   Uva - was the question to me? rrao11 05/18/19 05:04:42 PM
#83887   CELZ....I Think he knows what he's doing and gint1 05/18/19 04:46:18 PM
#83886   Warbington is supposed to file a form4 anytime Alexxdj1 05/18/19 04:06:53 PM
#83884   After MANY months of thought and analysis, the uvaphd 05/18/19 03:23:21 PM
#83883   What exactly did you mean about Warbington—I don’t uvaphd 05/18/19 03:22:37 PM
#83882   0.017 uplinkjim 05/18/19 02:03:50 PM
#83881   Where do you see stock price on close whitehotcoal 05/18/19 01:54:52 PM
#83880   Naw gint- The member of management that dumped justdafactss 05/18/19 01:27:11 PM
#83877   gint- EXACTLY!!! Who needs CELZ and for what? justdafactss 05/18/19 01:10:43 PM
#83874   SK- Yup, blue eyed blondes will definitely confirm it. justdafactss 05/18/19 12:26:17 PM
#83873   c2- Yep, boxes, not one pic touted of justdafactss 05/18/19 12:24:35 PM
#83871   NSX- Nothing OLD about 33,673,225 shares dumped into justdafactss 05/18/19 12:16:32 PM
#83870   I meant to put a thumbs up not cover2 05/18/19 12:03:28 PM
#83869   ?? cover2 05/18/19 12:02:40 PM
#83867   Team work. Grocery store said they’d give cover2 05/18/19 11:40:30 AM
#83864   If it’s so good. All your loved ones Alexxdj1 05/18/19 11:23:09 AM
#83863   LMAO monte379 05/18/19 11:08:07 AM
#83862   Mandatory 2 business days to file Form 4 justdafactss 05/18/19 09:27:24 AM
#83861   This is what the INVESTORS KNOW about CELZ.......but monte379 05/18/19 08:55:10 AM
#83860   For the new eyes.............. monte379 05/18/19 08:54:58 AM
#83857   Fully agree ten. +1. monte379 05/18/19 08:45:10 AM
#83856   who is that crazy who can sell a ten 05/18/19 08:35:01 AM
#83854   Wow I hope you are correct...I hope you Ksycheng 05/18/19 07:42:56 AM
#83853   Agree WinInLife 05/18/19 07:06:28 AM
#83852   Interesting comparison Gisano. I agree with you on WinInLife 05/18/19 07:06:07 AM
#83851   Nope. CELZ peaked at $0.07 on June 28th 2018. WinInLife 05/18/19 06:45:46 AM
#83850   If CMTH receives an offer for a b/o rrao11 05/18/19 05:46:41 AM
#83849   It was. Last summer. Looking for a repeat soon. Polebarn 05/18/19 03:35:48 AM
#83848   IMO, CELZ will be a target before end joh64 05/18/19 02:12:04 AM
#83847   WELL GL 2 YOU amigo. Chaka 05/18/19 01:34:44 AM
#83846   Loaded and ready to go. Picked up a big superbingo 05/18/19 01:24:26 AM
#83842   uplj- Do you have a receipt to back justdafactss 05/18/19 01:03:32 AM
PostSubject